Analytical Data
-
Gene name
IGIP
- Application
-
Alternative Names
IGIP；C5orf53；IgA-inducing Protein homolog
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A6NJ69
-
Expression Region
31-53aa
-
AA Sequence
KSPCGNQANVLCISRLEFVQYQS
-
Molecular Weight
56.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of IGIP (Interferon Gamma-Inducible Protein) recombinant proteins has garnered significant attention in recent years due to their potential applications in immunotherapy and infectious disease management. IGIPs are a family of proteins that are induced by interferon-gamma, a key cytokine involved in immune responses. These proteins play crucial roles in modulating immune signaling pathways, influencing the activity of various immune cells, and enhancing the body's defense mechanisms against pathogens. Research into IGIP recombinant proteins aims to understand their structure, function, and mechanisms of action, leading to the development of novel therapeutic strategies. By producing these proteins through recombinant DNA technology, scientists can investigate their biological properties in detail, facilitating the discovery of potential biomarkers for disease and novel treatments for conditions such as cancer, autoimmune diseases, and chronic infections. Moreover, the investigation of IGIP recombinant proteins is instrumental in elucidating the complexities of the immune response, providing insights that could inform vaccine development and enhance the efficacy of existing immunotherapies. Overall, the ongoing research into IGIP recombinant proteins represents a promising frontier in the fields of immunology and therapeutic development.
